《Gilead2015-4季度研发进展材料.pdf》由会员分享，可在线阅读，更多相关《Gilead2015-4季度研发进展材料.pdf（65页珍藏版）》请在金锄头文库上搜索。
1、Q4 2015 Earnings Results February 2, 2016 Forward-looking Statements 2 The projected financial results presented in the following slides represent managements estimates of Gileads future financial results. Gilead cautions readers that forward-looking statements are subject to certain risks and uncer
2、tainties that could cause actual results to differ materially. These risks and uncertainties include: Gileads ability to achieve its anticipated full year 2016 financial results; Gileads ability to sustain growth in revenues for its antiviral and other programs; availability of funding for state AID
3、S Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gileads earnings; the possibility of unfavorable results from clinical trials involving investigational compounds, i
4、ncluding GS-5734 and filgotinib; Gileads ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gileads earnings; Gileads ability to submit new drug applications for new product candidates
5、 in the timelines currently anticipated; Gileads ability to receive regulatory approvals in a timely manner or at all, for new and current products, including F/TAF, R/F/TAF and SOF/VEL; Gileads ability to successfully commercialize its products, including Genvoya; the risk that physicians and patie
6、nts may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; the risk that estimates of patients with HCV or anticipated patient demand may not be accurate; the risk that private and public payers may be reluctant to provide, or continue
7、 to provide, coverage or reimbursement for new products, including Sovaldi and Harvoni; Gileads ability to successfully develop its oncology, inflammation, cardiovascular and respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gileads product c
8、andidates; the potential for pricing pressure from additional competitive HCV launches or austerity measures in European countries and Japan that may increase the amount of discount required on Gileads products; Gileads ability to complete its share repurchase program due to changes in its stock pri
9、ce, corporate or other market conditions; Gileads ability to pay dividends under its dividend program and the risk that its Board of Directors may reduce the amount of the dividend; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange i
10、mpact on Gileads future revenues and pre-tax earnings; and other risks identified from time to time in Gileads reports filed with the U.S. Securities and Exchange Commission (SEC). In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and
11、 expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of
12、assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates. You are urged to consider statements that include the words may, will, would, could, should, might, believes, estimates, projects, potential, expects, plans, anticip
13、ates, intends, continues, forecast, designed, goal, or the negative of those words or other comparable words to be uncertain and forward-looking. Gilead directs readers to its press releases, Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 and other subsequent disclosure docum
14、ents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update
15、 any such forward-looking statements. This presentation includes GAAP and non-GAAP financial measures, a complete reconciliation between these two measures is available on the Companys website at within the investor section. Management believes this non-GAAP information is useful for investors, when
16、 considered in conjunction with Gileads GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gileads operating results as reported under U.S. GAAP. Q4 2015 Earnings Call Agenda Introduction Patrick OBrien, VP, Investor Relations Commentary Q FY 2015 $106
